期刊
VACCINE
卷 30, 期 28, 页码 4135-4143出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2012.04.075
关键词
HIV; Vaccine; Neutralizing antibody; Heterologous prime-boost immunization
资金
- China Comprehensive Integrated Programs for Research on AIDS (CIPRA) [U19AI51915]
- National Natural Science Foundation of China [81020108030]
- SKLID Development grant [2008SKLID101]
- National Key Projects on Major Infectious Diseases [2008ZX10001-010, 2012ZX10001-008]
- National Institute of Allergy and Infectious Diseases at the National Institutes of Health, USA
Objective: To develop an effective HIV vaccine strategy that can induce cross-reactive neutralizing antibody. Methods: Codon-optimized gp140 and gp145 env genes derived from HIV-1(cn54), a CRF07 B'/C recombinant strain, were constructed as DNA and recombinant Tiantan vaccinia (rTV) vaccines. The effect of heterologous immunization with gp140 and gp145 was tested in mice and guinea pigs. T cell responses were detected using the IFN-gamma ELISPOT assay. A panel of primary isolates of clade B' and B'/C HIV-1 and TZM-bl cells was used to determine the neutralizing activity of immunized sera. Results: The neutralizing antibodies (NAbs) induced by the heterologous immunogen immunization neutralized all HIV-1 B' and B'/C primary isolates in the guinea pig model. Gp145 and gp140 heterologous prime-boost induced the best neutralizing antibody response with a broad neutralizing spectrum and the highest titer of 1:270 at 6 weeks after the last inoculation. However, the T cell response to HIV-1 peptides was significantly weaker than the gp145+gp145 homologous prime-boost. Conclusions: This heterologous prime-boost immunization strategy could be used to design immunogengenerating broad neutralizing antibodies against genetic variance pathogens. (C) 2012 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据